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1. Introduction 
The mitochondrial 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) synthase deficiency (MIM 
600234) is an autosomic recessive inborn error of metabolism, hard to characterize and 
probably underdiagnosed (Thompson et al., 1997). The enzyme failure is caused by 
mutations in the gene HMGCS2, located in chromosome 1. The illness was first diagnosed in 
1997 (Thompson et al., 1997), in a six-year old boy, who presented a semicomatose state 
after three days with gastroenteritis and diet (Bouchard et al., 2001). Up to date, only eight 
patients have been reported with an estimated incidence of <1/1,000,000, although it 
could be higher because some patients probably have been misdiagnosed as Reye 
syndrome. 
The mitochondrial HMG-CoA synthase enzyme (mHS, EC 4.1.3.5) has a main role in the 
synthesis of the ketone bodies and in the HMG-CoA formation. Ketone bodies act as an 
alternative glucose fuel in a number of tissues as heart, muscle and brain, and have a critical 
role during metabolic stress and starving, situations where the symptoms of the disease 
appear. 
2. Ketogenesis 
The ketogenesis is a metabolic process that takes place inside the mitochondria. The acetyl-
CoA, originated during the fatty acids β-oxidation, is converted to acetoacetate, β-
hidroxybutyrate and acetone. These metabolites are known as ketone bodies and act as a 
glucose alternative fuel in many tissues as heart, skeletal muscle and brain. In brain, ketone 
bodies play an essential role in situations of hypoglycemia (Edmond, 1992; Zammit & Moir, 
1994). Besides their alternative fuel role, ketone bodies are lipogenic precursors too. They 
play a role during the myelinating process in the neonates’ brain (Nehlig & Pereira de 
Vasconcelos, 1993), and in a minor degree in the mammary gland during suckling (Zammit, 
1981). Moreover, they seem to have some functions in metabolism regulation (Robinson & 
Williamson, 1980).  
The main tissue where ketogenesis takes place is the liver (Zammit & Moir, 1994). However, 
it has been also found in kidney, adipose tissue (Thumelin et al., 1993), and intestine of 
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suckling rats (Hahn & Taller, 1987) and, in a minor degree, in cortical astrocytes of newborn 
rats (Cullingford et al., 1998; Blázquez et al., 1998). 
Ketone bodies can be elevated in physiological situations as: fasting, prolonged exercise, 
high-fat diet or pregnancy (Felig & Lynch, 1970), in the neonate (Hawkins et al., 1971); and 
in pathologic situations as: diabetes (Bates et al., 1968), obesity and disease of the glucose or 
glycogen metabolism (Mitchell et al., 1997). 
 
 
Fig. 1. Ketone bodies synthesis pathway 
The main pathway of ketone bodies from acetyl-CoA includes the following reactions 
(Figure 1): 
- In the first reaction, two acetyl-CoA molecules join to form acetoacetyl-CoA. This 
reaction is catalyzed by the acetoacetyl-CoA thiolase enzyme. 
- Then, acetoacetyl-CoA reacts with another acetyl-CoA to produce the HMG-CoA. This 
is a condensation reaction where the mHS enzyme is involved, and whose failure is 
responsible of the disease. 
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- In the third reaction, the HMG-CoA is cleaved into acetoacetate, the first ketone body 
produced, and acetyl-CoA. This step is catalyzed by the HMG-CoA lyase (HL).  
- Finally, in the last reaction, the acetoacetate is reduced to β-hydroxybutyrate, the 
second ketone body generated. The enzyme involved in this reaction is the β-
hydroxybutyrate dehydrogenase. Acetone is formed by the spontaneous 
decarboxylation of acetoacetate. 
There is an alternative ketogenic pathway different from the previously described, which 
takes place with substrates of aminoacids catabolism. Both pathways converge in the 
mitochondrial HL enzyme. 
3. mHS enzyme 
The mHS catalyzes the second reaction of the main pathway of the synthesis of ketone 
bodies and it is considered as the key enzyme of pathway regulation. 
3.1 Enzymatic reaction 
The mHS enzyme catalyzes the condensation of acetyl-CoA and acetoacetyl-CoA into HMG-
CoA. The HMG-CoA, produced inside the mitochondria, drives towards the formation of 
ketone bodies. The mHS catalyzed reaction follows a Bi Bi Ping-Pong substitution 
mechanism (Cleland, 1963; Miziorko et al., 1975). This reaction has three steps (Miziorko et 
al., 1977) (Figure 2): 
- Firstly, acetyl-CoA reacts with the thiol group of the catalytic Cys166 in order to produce 
a covalent intermediate form of the acetyl-enzyme. This is the limiting reaction step 
(Miziorko et al., 1977). 
- Then, acetoacetyl-CoA (second substrate) condenses with the intermediate product to 
give HMG-CoA, which will be attached to the enzyme by a covalent bond. 
- In the final step, HMG-CoA is released from the enzyme by hydrolysis. 
High concentrations of acetoacetyl-CoA inhibit the first reaction step, because it competes 
with acetyl-CoA for the active site of the enzyme (Page & Tubbs, 1978). Magnesium can act 
as an inhibitor of the reaction too. 
3.2 Protein structure 
Human mHS has 508 amino acids and its structure is a homodimer formed by two identical 
monomers linked by a salt bridge (Figure 3). At the N-terminal end is the leader peptide, 
with 37 aa, which drives the protein to the mitochondria. 
In 1985, the catalytic sequence of the enzyme was identified in a purified protein from 
chicken liver (Miziorko & Behnke, 1985). This sequence has 21 aa and a 100% homology 
with HMG-CoA synthases from other mammals. The catalytic aminoacid Cys129,  
whose human homolog is the Cys166, is located inside this region (Misra et al., 1995). The 
protein analysis shows three regions rich in proline, glutamine, serine and threonine, 
which could be PEST sequences (Pro-Glu-Ser-Thr) (Rogers et al., 1986). These regions  
are characterized by a quick turnover of proteins (Boukaftane et al., 1994; Ayté et al., 
1990). 
Recently, the human enzyme has been crystallized and its alpha/beta structure, with 17 beta 
sheets and 19 alpha helices, has been well characterized. The tunnel of substrate entry and 
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product exit is located outside of the molecule, at the opposite side of the interaction 
between the two monomers (Shafqat et al., 2010). 
 
 
A 
 
 
B 
Fig. 2. A. Acetyl-enzyme intermediate formation. B. HMG-CoA formation 
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Fig. 3. Structural location of missense mutations in human mHS, represented as blue spheres 
3.3 Enzyme expression 
Studies of gene expression in human tissues in basal conditions showed a tissue-specific 
expression. High mRNA levels are detected in the liver, the organ with the highest 
ketogenic capacity. Expression is also high in colon, which is related to the fermentative 
processes that take place in it (Mascaró et al., 1995). A minor level of mRNA expression has 
been observed in heart, skeletal muscle, gonads, kidney and pancreas (Mascaró et al., 1995; 
Royo et al., 1993). Studies in rats have found mRNA expression in cortical astrocytes from 
newborns (Cullingford et al., 1998; Blazquez et al., 1998), and in the intestine of suckling 
animals (Bekesi & Williamson, 1990; Thumelin et al., 1993; Serra et al., 1993). 
Changes in the level of gene expression have been reported during development. In 
suckling rats, the highest levels of expression were detected at the third day of life, 
decreasing progressively until weaning, when mRNA levels are similar to those of adult 
well fed rats (Serra et al., 1993). 
3.4 Enzyme regulation 
Production of ketone bodies in hepatic mitochondria is a complex and highly regulated 
process (Guzmán & Geelen, 1993; Zammit & Moir, 1994). Their synthesis increases in 
starving situations and in high fat intake, while it decreases after feeding or insulin 
administration and in the suckling-weaning transition (Williamson & Whitelaw, 1978; 
McGarry & Foster, 1980; Robinson et al., 1980). 
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Initially, the acyl-CoA input to the mitochondria was considered the principal check-point 
of ketogenesis (Guzman & Geelen, 1993; McGarry & Brown, 1997). However, later studies 
showed that the mHS enzyme can regulate ketogenesis (Williamson et al., 1968). Therefore, 
metabolic conditions that imply an increase of ketone bodies are linked to an increase of the 
levels of HMGCS2 gene expression (Casals et al., 1992) and of the mHS enzyme (Serrá et al., 
1993). Meanwhile, conditions that cause a decrease of the synthesis of ketone bodies are 
related to a decrease in the mRNA levels of the HMGCS2 gene (Casals et al., 1992) and of the 
mHS enzyme (Serrá et al., 1993). 
Currently, two check-points are recognized in the control of the synthesis of ketone bodies, 
one at the same step that of the Carnitine Palmitoyl Transferase 1 reaction, which provides 
the substrate acetyl-CoA, and another in the ketogenic pathway, at the step of the mHS 
enzyme (Williamson et al., 1968; Dashti & Ontko, 1979). Regulation of mHS is the most 
important step and depends on two mechanisms: a long term regulation of the transcription 
of the HMGCS2 gene (Casals et al., 1992; Hegardt, 1999), and a short term regulation of the 
protein. This one depends on succinyl and desuccinyl enzymes reactions (Lowe & Tubbs, 
1985; Quant et al., 1990). All of these mechanisms are influenced by nutritional and 
hormonal factors. 
3.5 Isoenzymes 
Two HMG-CoA synthase isoenzymes which catalyze the same reaction are known, 
however, they are located in different structures inside the cell. The mHS (Clinkenbeard et 
al., 1975) is involved in the synthesis of ketone bodies in the mitochondria, while the 
cytosolic HMG-CoA synthase (cHS) is critical for the synthesis of cholesterol (Clinkenbeard 
et al., 1975; Reed et al., 1975). 
Expression pattern of cHS is different from the one described for mHS. The cytosolic 
enzyme is expressed in most of the tissues, and its gene is considered a house-keeping gene. 
High mRNA levels are observed in liver followed by heart, placenta and pancreas (Mascaró 
et al., 1995). Their transcriptional regulation is different from the mHS and it is negatively 
regulated by cholesterol and other isoprenoids (Hua et al., 1993). 
The activity measures of the HMG-CoA synthase in a liver crude extract is divided between 
a 20-40% for the cHS and a 60-80% for the mHS (Clinkenbeard et al., 1975). Surprisingly, 
there is not reported any case with cHS deficiency.  
4. mHS deficiency  
Deficiency of mHS is an inborn error of metabolism that affects the synthesis of ketone 
bodies. It is a very rare autosomal recessive disorder reported in 1997 (Thompson et al., 
1997), in a six year old boy. The patient had hypoglycemia, hypoketonemia and 
semicomatous state, after three days with gastroenteritis and dieting. Symptoms quickly 
reversed after intravenous administration of glucose. Liver biopsy showed a decrease in the 
activity of mHS. Molecular study of the gene confirmed the diagnosis (Bouchard et al., 
2001). Generally, the disease shows unspecific clinical symptoms and metabolites excretion 
profile, sometimes attributed to a fatty acid β-oxidation enzyme defect and that makes it to 
be underdiagnosed. Some authors pointed out that it can be misdiagnosed as Reye 
syndrome and be associated with the sudden infant death syndrome (Thompson et al., 
1997). Symptoms usually appear after situations of starving and/or high energy expenditure 
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(fever, stress, exercise). In normal conditions, metabolic pathways that provide alternative 
glucose sources, as the synthesis of ketone bodies, are activated. A defect of ketogenesis can 
trigger a coma in the individual with low glucose availability. 
4.1 Clinical features 
In all the cases reported, clinical symptoms have appeared in childhood, specially during 
the first year of life; however, two of the 8 cases were diagnosed at the age of four and six 
years, respectively. 
Clinical features of mHS deficiency are unspecific (Table 1), which makes it hard to 
diagnose. Initial symptoms include vomiting and lethargy that can progress to coma. In 
most cases these symptoms are accompanied with hepatomegaly (Thompson et al., 1997) 
and in some cases with respiratory disease and encephalopathy. These symptoms quickly 
improve after glucose administration. Up to date, all the reported cases have had a favorable 
outcome, despite severe acute episodes. All the reported patients with mHS deficiency are 
still alive.  
4.2 Diagnosis 
4.2.1 Biochemical data 
Hypoglycemia is the main biochemical anomaly detected during an acute episode. Increase 
of the levels of plasmatic free fatty acids and urine dicarboxylic acids is also found. Plasma 
levels of acylcarnitines, lactate and ammonium are within normal limits (Morris et al., 1998). 
In some cases, metabolic acidosis has been reported (Table 1). 
This disease, as opposite to the HL deficiency, does not show a characteristic organic acids 
pattern in urine. The mHS substrate does not accumulate because it can be metabolized to 
acetyl-CoA during the β-oxidation. 
4.2.2 Enzyme activity 
An enzymatic assay in liver biopsy is needed to confirm the mHS deficiency, because liver is 
the tissue with the highest enzyme expression. This method has several limitations, being 
the main one that in liver homogenate we cannot distinguish between mHS and cHS 
enzyme activity. This problem impairs the interpretation of the results and explains that the 
assay has only been carried out in two patients (Thompson et al., 1997; Morris et al., 1998). 
The possibility to use other tissues or alternative cells as lymphocytes or fibroblasts has been 
proposed, but the low expression levels in these tissues did not allow investigators to obtain 
valid measurable levels (Thompson et al., 1997). 
4.2.3 Molecular diagnosis 
Molecular analysis is the method of choice to confirm the clinical diagnosis. It is done from 
genomic DNA of the patient, by PCR amplification and sequencing of the HMGCS2 gene.  
4.2.4 Differential diagnosis with HMG-CoA lyase deficiency 
The HL is the immediately posterior to mHS enzyme in the pathway of the ketone bodies 
synthesis. HL deficiency (3-hydroxy-3-methylglutaric aciduria) has very similar clinical 
manifestations to mHS deficiency, although there are significant differences that the 
clinicians should know in order to differentiate them. 
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 Signs and laboratory data mHS deficiency HL deficiency 
S
IG
N
S
 
Encephalopathy +/- +/- 
Hypotonia - +/- 
Lethargy +/- +/- 
Abnormal Breathing +/- +/- 
Coma +/- +/- 
Hepatomegaly + +/- 
Normal development + +/- 
Death - +/- 
B
IO
C
H
E
M
IC
A
L
 D
A
T
A
 
Hypoglycaemia + + 
Hypoketonemia + + 
Hyperammonemia - +/- 
Transaminase +/- +/- 
Metabolic acidosis +/- + 
High urine dicarboxylic acid  + - 
High 3-hydroxy-3-methylglutaric, 3-
hydroxyisovaleric, 3-methylglutaconic 
and 3-methylglutaric acids 
- + 
Normal level of carnitine + +/- 
+Always; -Never; +/- Sometimes. 
Table 1. Signs and Biochemical data of mHS and HL deficiency 
Patients with HL deficiency may present acute crisis as well, during the neonatal or early 
infancy periods. Both diseases appear when exogenous supply of glucose fails (fasting 
periods), or when excessive glucose consumption exists (stress, fever or exercise). In the 
majority of patients with mHS deficiency, the acute crisis begins with hepatomegaly and 
superficial coma. However, in HL deficiency, or other β-oxidation enzymes, symptoms of 
the deficiency usually involve several tissues (Thompson et al., 1997). In the latter, most of 
the patients show muscular weakness and myopathy (Ribes et al., 2003). In the HL 
deficiency symptoms as dehydration, hypotonia, hypothermia, tachypnea, lethargy, coma 
and even death, have been reported (Wysocki & Hahnel, 1986; Menao et al., 2009). Up to 
date, no patient with mHS deficiency has died due to this disease. 
Complications of 3-hydroxy-3-methylglutaric aciduria include, macrocephaly (Stacey et al., 
1985), development delay and dilated cardiomyopathy with arrhythmia (Gibson et al., 
1994). Microcephaly has been reported in one patient (Lisson et al., 1981). Up to date, no 
complications have been reported in patients with mHS deficiency. 
The most important difference between both diseases is found in the urine profile of the 
organic acids, which is characteristic only in HL deficiency. Metabolites that accumulate in 
urine are the 3-hydroxy-isovaleric acid, the 3-methylcrotonyl glycine, the 3-methylglutaric 
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acid, the 3-methylglutaconic acid and the 3-hydroxy-3-methylglutaric acid. Neither of these 
metabolites is increased in mHS deficiency. Clinical and biochemical data of both 
deficiencies are included in Table 1.  
4.3 Treatment 
Treatment is symptomatic during acute episodes and consists of intravenous administration 
of glucose to correct hypoglycemia. Long-term maintenance therapy includes low-fat diet 
and avoidance of fasting periods of more than 12 hours. It is also important to avoid 
situations of metabolic stress, mainly produced by recurrent illness that can be prevented by 
extra caloric intake (Morris et al., 1998). 
5. HMGCS2 gene 
Although mHS is codified by a gene (Ayte et al., 1990) different from the cHS gene (Gil et 
al., 1986), their high homology suggests a common origin about 500 millions years ago, 
when vertebrates appeared (Boukaftane et al., 1994). 
Human HMGCS2 gene is located in chromosome 1 (1p12-p13), between the markers WI-
7519 and D1S514. It has 10 exons and 9 introns, with a total size of 21,708 bp (Figure 4). 
Exons length oscillates between 107 and 846 bp, and the intron’s size varies between 0.4 and 
4.1 kDa.  cDNA has a total size of 2,082 bp. 
So far, no splice variants of the gene have been experimentally confirmed, although the 
current Expressed Sequence Tag database includes a variant with a deletion of exon 4. 
5.1 Mutation update 
Up to date, 8 patients have been diagnosed by molecular analysis. Among them nine allelic 
variants have been identified: seven missense variants, one nonsense and one intronic 
mutation (Figures 3 and 4). One of these variants, the Y167C, affects to a closed Cys166 amino 
acid, which is considered the catabolic site of the enzyme (Hegard, 1999). The nonsense 
variant R424X (Bouchard et al., 2001; Morris et al., 1998), produced a truncated protein of 
424 amino acids that probably cannot be incorporated into the active protein dimer. The 
intronic mutation is located in the first nucleotide of the intron 5 (c.1016+1G>A). In general, 
this type of mutations produces the deletion of the affected exon (exon 5 in this case), 
although in this disease the mechanism has not been confirmed (Zschocke et al., 2002). 
In order to prove the effect of the mutation in the enzyme activity, protein over-expression 
has been tried with recombinant DNA techniques although with no success (Bouchard et al., 
2001). 
 
 
Fig. 4. Scheme of the mutations located in the human gene HMGCS2 
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No clinical data were available from the patients who carried these mutations. 
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Another approach consisted in studying, with an indirect method, the mutation effect in 
MEV-1 cell cultures (Aledo et al., 2001). These studies were based in the cell mevalonate 
auxotrophy correction when they are transfected with cDNA of the HMGCS2 gene. The 
expression of the mHS gene gives to MEV-1 cells the capacity to synthesize HMG-CoA 
inside the mitochondria, which is transformed in mevalonate and cholesterol (Ortiz et al., 
1994). As expected, the mutated mHS cDNA transfection does not correct the MEV-1 cells 
auxotrophy, which proves the deficiency of HMG-CoA synthesis. 
Recently, new mutations in mHS deficiency patients have been reported, but no clinical 
information was given. There are 8 missense mutations and one nonsense (Shafqat et al., 
2010). 
In Table 2 an updated list of mutations reported in the HMGCS2 gene is displayed, together 
with the patients´ clinical data. 
6. Genotype-phenotype correlations 
With the current knowledge available, it is difficult to establish strong genotype-phenotype 
correlations, among other reasons, for instance, because we ignore relevant information 
such as the levels of enzyme activity in affected patients. The seriousness of the disease may 
be more related to the agent that triggered hypoglycemia and to the time without treatment 
than with the mutation itself. 
7. Conclusion  
Although mHS deficiency is an extremely rare disease, it is likely underdiagnosed and its 
prevalence is higher than estimated. Pediatricians may suspect this disorder in infants with 
vomiting, mild hepatomegaly, hypoglycemia, metabolic acidosis, increased levels of  
plasmatic free fatty acids and dicarboxylic aciduria, specially if symptoms appeared after a 
situation of metabolic stress, usually due to dieting in a gastroenteritis or during an infection 
process. Currently, the only reliable diagnostic –confirmatory- test is the molecular analysis 
of the gene, since measurements of the levels of enzymatic activity are masked by the 
activity of isoenzyme cHS. 
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